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1. Y‐BOX BINDING PROTEIN‐1 TRANSCRIPTIONALLY ACTIVATES ABC TRANSPORTER GENE CONFERRING CANCER‐ACQUIRED MULTIDRUG RESISTANCE {#cas14006-sec-0001}
===========================================================================================================================

One of the most significant obstacles to anticancer therapy is the emergence of drug‐resistant tumors. Development of potent therapeutic drugs that can overcome drug resistance is a persistent challenge for cancer researchers. Over the past five decades, the classical approach of selecting drug‐resistant cancer cells through chronic exposure of drug‐sensitive cancer cells to anticancer agents has been used to elucidate how cells acquire drug resistance, in addition to how drug resistance‐reversal therapies are developed.[1](#cas14006-bib-0001){ref-type="ref"}, [2](#cas14006-bib-0002){ref-type="ref"}

One representative ABC transporter gene, *ABCB1*, encodes a membrane glycoprotein catalyzing the ATP‐dependent efflux of multiple anticancer agents, and the efflux activity is closely associated with the acquisition of the most classical multidrug resistance (Figure [1](#cas14006-fig-0001){ref-type="fig"}A).[3](#cas14006-bib-0003){ref-type="ref"}, [4](#cas14006-bib-0004){ref-type="ref"} In one example, the same drug‐sensitive parental cell line was used to select two multidrug‐resistant cell lines; KB‐C1[5](#cas14006-bib-0005){ref-type="ref"} was selected as colchicine‐resistant cells and KB/VJ300[6](#cas14006-bib-0006){ref-type="ref"} was selected as vincristine‐resistant cells. *ABCB1* is amplified in resistant KB‐C1 cells,[7](#cas14006-bib-0007){ref-type="ref"} and the amplified region spans approximately 1‐2 Mb on the human chromosome 7q21.12.[8](#cas14006-bib-0008){ref-type="ref"} In contrast, overexpression of the ABCB1 protein was also observed in resistant KB/VJ300 cells without gene amplification.[6](#cas14006-bib-0006){ref-type="ref"} Therefore, *ABCB1* is overexpressed through either gene amplification or transcriptional activation. Among 51 ABC transporters, *ABCB1* is one of the major transporters of clinical significance.[9](#cas14006-bib-0009){ref-type="ref"} As a major mechanism of ABCB1 overexpression, transcriptional activation of *ABCB1* is most often reported in various human malignancies and in cancer cell lines (Figure [1](#cas14006-fig-0001){ref-type="fig"}A). Y‐box binding protein‐1 (YBX1) binds to the Y‐box sequence in the 5′‐flanking region of *ABCB1* in drug‐resistant cancer cells to promote its transcriptional activation (Figure [1](#cas14006-fig-0001){ref-type="fig"}A,B).[10](#cas14006-bib-0010){ref-type="ref"}, [11](#cas14006-bib-0011){ref-type="ref"}, [12](#cas14006-bib-0012){ref-type="ref"}, [13](#cas14006-bib-0013){ref-type="ref"} In addition, YBX1 binds to the Y‐box sequence in many other drug resistance‐related genes (Figure [1](#cas14006-fig-0001){ref-type="fig"}B).[11](#cas14006-bib-0011){ref-type="ref"}, [14](#cas14006-bib-0014){ref-type="ref"}, [15](#cas14006-bib-0015){ref-type="ref"}, [16](#cas14006-bib-0016){ref-type="ref"}, [17](#cas14006-bib-0017){ref-type="ref"}, [18](#cas14006-bib-0018){ref-type="ref"}, [19](#cas14006-bib-0019){ref-type="ref"}, [20](#cas14006-bib-0020){ref-type="ref"} Therefore, YBX1 drives the acquisition of drug resistance in cancer cells through its transcriptional activation.[21](#cas14006-bib-0021){ref-type="ref"}, [22](#cas14006-bib-0022){ref-type="ref"}, [23](#cas14006-bib-0023){ref-type="ref"}

![A, Among 51 ABC transporters, ABCB1 is a representative transporter that enhances outward efflux activity of anticancer drugs from the inside to the outside of cancer cells, resulting in acquired multidrug resistance. Enhanced transcriptional activation of *ABCB1*, either by chronic exposure to anticancer drugs or by acquired multidrug resistance, is mediated through the environmental stimuli‐naïve Y‐box binding protein‐1 (*YBX1*). B, YBX1‐induced activation of *ABCB1* is first presented as a transcriptional mechanism of how tumor multidrug resistance is acquired during chemotherapeutic treatments in various human malignancies. *YBX1* also induces activation of various other resistance‐related genes, including *MVP/LRP*,*TOP2A*,*CD44*,*CD49f*,*BCL2*,*MYC*, and androgen receptor (AR). C, Structure and phosphorylation sites of the YBX1 protein. Phosphorylation at Ser102 in the cold shock domain is essential for nuclear translocation and oncogenic activation of *YBX1*. B/A repeat, basic and acidic amino acid repeat sequences](CAS-110-1536-g001){#cas14006-fig-0001}

YBX1 is a member of the cold shock domain protein superfamily, which is considered the most evolutionarily conserved nucleic acid‐binding protein from bacteria to human (Figure [1](#cas14006-fig-0001){ref-type="fig"}C).[21](#cas14006-bib-0021){ref-type="ref"}, [24](#cas14006-bib-0024){ref-type="ref"} YBX1 was initially identified as a transcription factor that binds to the Y‐box sequence of the 5′‐flanking region of the ovalbumin gene,[25](#cas14006-bib-0025){ref-type="ref"} the major histocompatibility complex class gene,[26](#cas14006-bib-0026){ref-type="ref"} and of epidermal growth factor receptor (*EGFR*).[27](#cas14006-bib-0027){ref-type="ref"} The consensus sequence binding site for YBX1 is 5′‐CTGATTGG‐3′, namely, the inverted CCAAT box (Figure [1](#cas14006-fig-0001){ref-type="fig"}B).

YBX1 is localized in both the cytoplasm and nucleus of cancer cells (Figure [2](#cas14006-fig-0002){ref-type="fig"}A). YBX1 translocates from the cytoplasm to the nucleus when exposed to various environmental stimuli in vitro and in vivo,[11](#cas14006-bib-0011){ref-type="ref"}, [12](#cas14006-bib-0012){ref-type="ref"}, [28](#cas14006-bib-0028){ref-type="ref"}, [29](#cas14006-bib-0029){ref-type="ref"} as well as in cancer cells in patients treated with anticancer therapeutic drugs.[30](#cas14006-bib-0030){ref-type="ref"} YBX1 in the nucleus plays a major role as a transcription factor for various drug resistance‐related genes, including *ABCB1*, and in the repair of damaged DNA. However, in the cytoplasm, YBX1 is mainly involved in post‐transcriptional control of several mRNA splices, including epithelial‐to‐mesenchymal transition‐related genes.[31](#cas14006-bib-0031){ref-type="ref"}, [32](#cas14006-bib-0032){ref-type="ref"} In the present review, we focus on the oncogenic role of YBX1, its localization in the nucleus, and its association with drug resistance.

![A, Representative immunohistochemistry images of Y‐box binding protein‐1 (YBX1) in the cytoplasm and nucleus of breast cancer tissues when stained with antibodies recognizing YBX1. B, Simplified model of how YBX1 induces resistance to anticancer drugs in cancer cells when it is located in the nucleus. Nuclear YBX1 induces activation of the genes involved in drug resistance and malignant progression](CAS-110-1536-g002){#cas14006-fig-0002}

2. Y‐BOX BINDING PROTEIN‐1 DYSREGULATES GENES INVOLVED IN DRUG RESISTANCE AND TUMOR GROWTH PROMOTION {#cas14006-sec-0002}
====================================================================================================

Immunohistochemistry (IHC) analyses have mainly been used to investigate whether nuclear and/or cytoplasmic expression of YBX1 is enhanced in cancer.[28](#cas14006-bib-0028){ref-type="ref"} Figure [2](#cas14006-fig-0002){ref-type="fig"}A presents typical IHC images of YBX1 expression in the cytoplasm and in the nucleus of cancer cells in tumor specimens from cancer patients.

YBX1 dysregulates drug resistance‐related genes, including *ABCB1*,*MVP/LRP*,*PCNA*,*MYC*,*TOP2A*,*CD44*,*CD49f*,*p53*,*BCL2*, and androgen receptor (*AR*), conferring resistance to cancer cells against a wide range of anticancer therapeutic agents. For example, enhanced YBX1 expression is often correlated with cisplatin resistance, a representative cytotoxic anticancer drug.[11](#cas14006-bib-0011){ref-type="ref"}, [12](#cas14006-bib-0012){ref-type="ref"}, [33](#cas14006-bib-0033){ref-type="ref"} Conversely, YBX1 also dysregulates genes involved in cell proliferation and cell cycle, such as *EGFR*, human epidermal growth factor receptor 2 (*HER2*), cyclins A/B1/D1/E, *CDC6*, and *AR*. Overall, YBX1 enhances the expression of genes involved in cell proliferation, cell cycle, survival, and drug resistance and facilitates malignant progression as well as acquired resistance to anticancer chemotherapeutics by cancer cells (Figure [2](#cas14006-fig-0002){ref-type="fig"}B).

3. ENHANCED YBX1 EXPRESSION PREDICTS POOR OUTCOMES IN VARIOUS HUMAN MALIGNANCIES {#cas14006-sec-0003}
================================================================================

Kamura et al[34](#cas14006-bib-0034){ref-type="ref"} first showed the clinical significance of nuclear YBX1 expression in predicting the expression of *ABCB1* and poor outcomes in ovarian tumors. To date, based on expression levels of YBX1 in cancer cells, when assessed using IHC or qRT‐PCR, almost all 70 independent studies have consistently shown a close relationship between enhanced expression of YBX1 and poor outcomes in over 20 human tumor types (Table [1](#cas14006-tbl-0001){ref-type="table"}, Doc [S1](#cas14006-sup-0001){ref-type="supplementary-material"}). Enhanced nuclear/cytoplasmic expression of YBX1 is negatively associated with overall survival or disease‐free survival in patients with various malignancies. In particular, nuclear YBX1 expression in cancer cells is significantly associated with poor outcomes in various malignancies, including breast, ovary, prostate, colon, liver, lung, bone, soft tissue, thyroid, skin, and nervous system, as well as osteosarcomas and hematological tumors (Table [1](#cas14006-tbl-0001){ref-type="table"}, Doc [S1](#cas14006-sup-0001){ref-type="supplementary-material"}). In addition, enhanced expression of YBX1 is positively correlated with various biomarkers, including *ABCB1*,*MVP/LRP*,*EGFR*,*HER2*,*AR*, and *CDC6*, and negatively correlated with estrogen receptor α (ERα), in various tumor types. Therefore, the enhanced expression of YBX1 could be a prognostic biomarker for cancer progression, potentially because of its tumor‐promoting effects on cell proliferation, survival, and drug resistance in various tumor types. Similarly, carcinogenesis and further malignant progression of cancer are associated with the nine hallmarks of cancer, including cell proliferation, survival, immortalization, inflammation, invasion, metastasis, and others.[35](#cas14006-bib-0035){ref-type="ref"} In addition, most of the hallmarks are closely coupled with enhanced expression of YBX1.[32](#cas14006-bib-0032){ref-type="ref"}

###### 

Association of YBX1 expression with outcomes and biomarkers in human malignancies[a](#cas14006-note-0001){ref-type="fn"}

  Human malignancies                                                Biomarkers associated with YBX1                                No. of published papers[b](#cas14006-note-0002){ref-type="fn"}
  ----------------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------
  Breast cancer                                                     ABCB1, EGFR, HER2, E2F‐1, CDC6, ER, EGR‐1, ER effector genes   19
  Lung cancer                                                       PCNA, HER2, HER3, CDC25a, MACC1                                7
  Ovarian cancer                                                    CD44, ABCB1, LRP/MVP, amphiregulin                             7
  Prostate cancer                                                   AR                                                             6
  Colorectal cancer                                                 EGFR, topoisomerase IIα, PCNA                                  5
  Gastric cancer                                                    HER2, CDC6                                                     4
  16 different tumor types[c](#cas14006-note-0003){ref-type="fn"}   ABCB1, EGFR, HER2, EXH2, Cyclin A1/D1, AKT, LRP/MVP            1‐3/each cancer

Augmented nuclear and/or total (nuclear/cytoplasmic) expression of YBX1 predicts poor outcomes in patients with human malignancies in close association with aberrant expression of various biomarkers and genes. Poor outcomes are mainly assessed using overall survival or disease‐free survival, but some reports referred to histological grade, tumor grade, and metastasis.

References are listed in Doc [S1](#cas14006-sup-0001){ref-type="supplementary-material"}.

Additional 16 tumor types include diffuse large B‐cell lymphoma, uterine cervical cancer, hepatocellular carcinoma, renal cell carcinoma, osteosarcoma, glioblastoma, nasopharyngeal carcinoma, laryngeal squamous cell carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, thyroid neoplasm, melanoma, rhabdomyosarcoma, synovial sarcoma, neuroblastoma, and non‐Hodgkin lymphoma.

AR, androgen receptor; EGFR, epidermal growth factor receptor; EGR‐1, early growth response protein 1; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PCNA, proliferating cell nuclear antigen; YBX1, Y‐box binding protein‐1.
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4. Y‐BOX BINDING PROTEIN‐1 IS AN EFFECTIVE POTENT TARGET IN OVERCOMING ANTI‐ESTROGEN RESISTANCE BY BREAST CANCER {#cas14006-sec-0004}
================================================================================================================

Among the numerous human tumor types, the clinical significance of YBX1 has been most extensively studied in breast cancer (Table [1](#cas14006-tbl-0001){ref-type="table"}, Doc [S1](#cas14006-sup-0001){ref-type="supplementary-material"}). Enhanced expression of YBX1 is predictive of poor outcomes in patients with breast cancer.[36](#cas14006-bib-0036){ref-type="ref"}, [37](#cas14006-bib-0037){ref-type="ref"}, [38](#cas14006-bib-0038){ref-type="ref"}, [39](#cas14006-bib-0039){ref-type="ref"}, [40](#cas14006-bib-0040){ref-type="ref"}, [41](#cas14006-bib-0041){ref-type="ref"} Adjuvant endocrine therapy and chemotherapy treatments have been used extensively in the treatment of breast cancer.[42](#cas14006-bib-0042){ref-type="ref"}, [43](#cas14006-bib-0043){ref-type="ref"} However, the emergence of refractory tumors is a major complication for breast cancer patients treated with adjuvant endocrine therapy.[44](#cas14006-bib-0044){ref-type="ref"} Targeting YBX1 may facilitate overcoming anti‐estrogen resistance and malignant progression in breast cancer based on the following reasons: YBX1‐knock‐in mice induce breast cancers with diverse histological characteristics, implicating YBX1 as an oncoprotein for mammary tumors;[45](#cas14006-bib-0045){ref-type="ref"} YBX1 overexpression promotes tumorigenesis in mammary epithelial cells;[46](#cas14006-bib-0046){ref-type="ref"} YBX1 silencing induces marked downregulation of cell proliferation and cell cycle‐related genes, such as *HER2*,*FGFR2*, and *CDC6*, and upregulation of *ER*α in human breast cancer cell lines,[36](#cas14006-bib-0036){ref-type="ref"}, [37](#cas14006-bib-0037){ref-type="ref"}, [47](#cas14006-bib-0047){ref-type="ref"}, [48](#cas14006-bib-0048){ref-type="ref"}, [49](#cas14006-bib-0049){ref-type="ref"}, [50](#cas14006-bib-0050){ref-type="ref"} conferring enhanced responsiveness to endocrine therapeutics in breast cancer cells.[50](#cas14006-bib-0050){ref-type="ref"} In addition, YBX1 overexpression induces downregulation of ERα expression in breast cancer cells (Figure [3](#cas14006-fig-0003){ref-type="fig"}A) and acquired resistance to tamoxifen, a representative anti‐estrogen, in therapeutic experimental models in vivo (Figure [3](#cas14006-fig-0003){ref-type="fig"}B).[47](#cas14006-bib-0047){ref-type="ref"}

![A, Immunohistochemistry images show reduced expression of estrogen receptor α (ERα) when Y‐box binding protein‐1 (YBX1) is overexpressed in mammary tumors induced by doxycycline in an experimental therapeutic model (Tet mock vs Tet YBX1). B, Overexpression of YBX1 in ERα‐positive breast cancer cells also induces resistance to endocrine therapy by tamoxifen in a xenograft experimental Tet YBX1 model compared with its Tet mock control. C, YBX1 expression is inversely correlated with ERα expression in human breast cancer. Heat map analysis of YBX1, ERα, and Ki67 in mammary tumors of breast cancer patients. D, Venn diagram showing the overlap of 322 genes between the top 500 genes that are positively correlated with *YBX1* and the top 500 genes that are negatively correlated with estrogen receptor 1 (*ESR1*). Several representative genes are presented. E, Venn diagram showing the overlap of 352 genes between the top 500 genes that are positively correlated with *ESR1* and the top 500 genes that are negatively correlated with YBX1. Several representative genes are presented](CAS-110-1536-g003){#cas14006-fig-0003}

YBX1 expression is also negatively correlated with ERα expression in breast cancer cells in vitro and in vivo.[36](#cas14006-bib-0036){ref-type="ref"}, [47](#cas14006-bib-0047){ref-type="ref"} Expression levels of *YBX1* mRNA are inversely correlated with expression levels of *ER*α mRNA and positively correlated with the expression of *Ki67*, a representative tumor growth marker, in breast cancer patients (The Cancer Genome Atlas \[TCGA\] database, n = 825)[51](#cas14006-bib-0051){ref-type="ref"} (Figure [3](#cas14006-fig-0003){ref-type="fig"}C). The top 500 genes that are positively or negatively correlated with *YBX1* or estrogen receptor 1 (*ESR1*) have been identified based on RNA‐seq data from a cohort of 825 patients with invasive breast cancer (Figure [3](#cas14006-fig-0003){ref-type="fig"}D,E).[37](#cas14006-bib-0037){ref-type="ref"}, [51](#cas14006-bib-0051){ref-type="ref"} In the present study, 352 of the top 500 genes were shown to be both positively correlated with *ESR1* and negatively correlated with *YBX1* (Figure [3](#cas14006-fig-0003){ref-type="fig"}E).[37](#cas14006-bib-0037){ref-type="ref"}, [51](#cas14006-bib-0051){ref-type="ref"} Therefore, the enhanced expression of YBX1 is reciprocally associated with reduced expression of various ERα‐targeted genes, indicating that YBX1 preferentially promotes ERα‐independent tumor growth and survival. The findings suggest that YBX1 has oncogenic potential in breast cancer and that YBX1 could be a therapeutic target in breast cancer refractory to endocrine therapeutics.

5. PHOSPHORYLATION AND NUCLEAR LOCALIZATION OF YBX1 ARE REQUIRED FOR ITS ONCOGENIC DRIVER FUNCTIONS {#cas14006-sec-0005}
===================================================================================================

Nuclear localization of YBX1 predicts poor outcomes in patients with various cancers (Table [1](#cas14006-tbl-0001){ref-type="table"}, Doc [S1](#cas14006-sup-0001){ref-type="supplementary-material"}). Therefore, future studies should investigate the mechanisms by which YBX1 in the nucleus functions as an oncogenic transcription factor for various effector genes associated with malignant progression. Figure [4](#cas14006-fig-0004){ref-type="fig"}A presents representative images of phosphorylated YBX1 (pYBX1 Ser102) in the nucleus of cancer cells in malignantly progressive tumors from patients. Phosphorylation of YBX1 at Ser102 is essential for its nuclear translocation in cancer cells. YBX1 Ser102 phosphorylation is suppressed by inhibitors of PI3K, mTORC1, and p90 ribosomal S6 kinase (RSK).[29](#cas14006-bib-0029){ref-type="ref"}, [52](#cas14006-bib-0052){ref-type="ref"}, [53](#cas14006-bib-0053){ref-type="ref"}, [54](#cas14006-bib-0054){ref-type="ref"} Figure [4](#cas14006-fig-0004){ref-type="fig"}B shows the suppression of nuclear localization by a PI3K inhibitor ([LY294002](LY294002)) or an mTORC1 inhibitor (everolimus). Consistent with Figure [4](#cas14006-fig-0004){ref-type="fig"}B, an Ser102 phosphorylation‐null mutant construct of YBX1 could not be translocated into the nucleus, which was accompanied by downregulated expression of EGFR and HER2, in breast cancer cells.[52](#cas14006-bib-0052){ref-type="ref"} Therefore, various kinases involved in AKT/mTOR and MEK/ERK signaling pathways influence both the phosphorylation and nuclear translocation of YBX1 (Figure [4](#cas14006-fig-0004){ref-type="fig"}C).

![A, Representative immunohistochemistry images of expression of phosphorylated Y‐box binding protein‐1 (pYBX1) with an antibody recognizing pYBX1 Ser102 in breast cancer tissues. pYBX1 is preferentially localized in the nucleus of cancer cells in patients with progressive cancer. Left panel shows the negative control. B, Inhibitors of both PI3K/AKT (LY294002) and mTORC1 (everolimus) suppress nuclear localization of YBX1 in cancer cells. C, Hypothetical model of how YBX1 is activated through its phosphorylation at Ser102. YBX1 is phosphorylated and activated by PI3K/AKT/mTORC1 and/or MEK/ERK signaling pathways, promoting nuclear translocation](CAS-110-1536-g004){#cas14006-fig-0004}

6. TARGETING YBX1 CONTRIBUTES TO FURTHER DEVELOPMENT OF EFFECTIVE ANTICANCER THERAPEUTICS {#cas14006-sec-0006}
=========================================================================================

Preclinical therapeutic studies targeting YBX1 itself have been assessed. A molecular decoy cell permeable peptide of nine amino acids that flank the YBX1 Ser102 site induced cytotoxicity in cancer cells in vitro.[55](#cas14006-bib-0055){ref-type="ref"} Other preclinical therapeutic approaches involving the silencing of *YBX1* with siRNAs or miRNAs have been carried out. A Dectin‐1‐targeting vehicle delivering YBX1 antisense DNA has been developed by making use of a novel polysaccharide drug delivery system, and the *YBX1* silencing approach showed some suppression effects on cell viability in vitro.[56](#cas14006-bib-0056){ref-type="ref"} Another study has reported that silencing of YBX1 expression using long noncoding RNA induces cell growth suppression in lung cancer cells.[57](#cas14006-bib-0057){ref-type="ref"} Such preclinical trials show some cytotoxic effects on cancer cells in vitro, and more therapeutic experiments in vivo are required.

The next approach would be to develop drugs that specifically target YBX1 activation processes in cancer cells (Figure [5](#cas14006-fig-0005){ref-type="fig"}). One crucial role of YBX1 with regard to its oncogenic potential involves transcriptional activation of various effector genes that are closely associated with cell proliferation, survival, and drug resistance. Tumor growth and survival most often depend on AKT/mTOR and/or RAF/MEK signaling pathways in various human malignancies, and their downstream effector, YBX1, functions as a potent oncogenic driver (Figure [5](#cas14006-fig-0005){ref-type="fig"}). Ichikawa and colleagues recently developed a novel multikinase inhibitor that targets AKT, p90RSK, and p70S6K, and the compound shows potent antitumor activities against various tumor types with YBX1 Ser102 phosphorylation.[58](#cas14006-bib-0058){ref-type="ref"} Targeting AKT/mTOR/p70S6K and/or MEK/ERK/p90RSK signaling pathways results in the inhibition of the activation of YBX1, and such targeting would be useful in the development of novel therapeutics that are effective in overcoming drug resistance (Figure [5](#cas14006-fig-0005){ref-type="fig"}).

![Model depicting how novel drugs targeting the Y‐box binding protein‐1 (YBX1) activation pathway overcome drug resistance. YBX1 is phosphorylated by Ser/Thr kinases involving AKT/mTOR/p70S6K and/or MEK/ERK/p90RSK signaling pathways. Phosphorylated YBX1 induces oncogenic transcriptional activation of various *YBX1* targeted genes and plays crucial roles in cell proliferation, survival, and drug resistance. Development of inhibitors of the activation pathways of YBX1 would facilitate overcoming intrinsic and acquired resistance in addition to malignant progression](CAS-110-1536-g005){#cas14006-fig-0005}

In conclusion, YBX1 plays essential roles in innate and acquired tumor drug resistance through the upregulation of a wide range of resistance‐related genes. Development of therapeutic drugs by targeting YBX1 phosphorylation would further facilitate overcoming tumor resistance to anticancer therapeutics in various progressive cancers. A future critical step would be the development and clinical evaluation of YBX1‐targeted therapeutics in patients with progressive cancers.
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